Sun Pharma and Philogen Ink Pact to commercialise speciality cancer drug

Sun Pharma announced that they have signed a worldwide licensing deal to market Philogen's specialty anti-cancer immunotherapy Fibromun (L19TNF) from Switzerland and Italy. bPhilogen is conducting registration trials for Fibromun to treat soft tissue sarcoma and glioblastoma (malignant brain tumors).

Sun Pharma will be the only company allowed to market Fibromun globally as per the agreement terms. Philogen will finish the current essential clinical trials for the product, seek marketing approval from regulatory agencies, and produce commercial supplies. Sun Pharma will take charge of commercialization tasks.

“Fibromun’s progress through development has been quite encouraging and it has potential to be an important option for treatment of soft-tissue sarcomas and other cancers with significant unmet medical needs," said Dilip Shanghvi, chairman and managing director of Sun Pharma.

“Our group has published data reflecting the promising therapeutic activity of Fibromun in glioblastoma, inducing long-lasting anti-tumor responses in a subset of patients. We have also announced that an independent monitoring board has evaluated safety and efficacy data of the pre-planned interim analysis of our Phase III clinical trial in soft tissue sarcoma and recommended continuing the study as planned by the protocol. In view of these promising developments, both companies are committed to the development and commercialization of Fibromun, making it widely available to patients who may benefit from it,” said Dr. Dario Neri, CEO and CSO of Philogen.